

Responsible Business & Sustainability

2023 BeiGene Highlights

Advancing Global Health

- Innovative Products
- Patient Access, Engagement & Advocacy



Empowering Our Colleagues

- Diversity, Equity, Inclusion & Belonging
- Engagement, Well-Being & Volunteerism



Innovating Sustainably

- Climate & Environmental Impact
- Product Stewardship



Operating Responsibly

- Integrity, Governance & Risk Management
- Responsible Sourcing



Advancing Global Health



65+

countries and regions in which our medicines are approved

~90

clinical trials currently ongoing

1M+

BRUKINSA and TEVIMBRA have treated more than 1M patients



2024 GOALS

Bring multiple high quality new molecules from discovery into clinic annually

Spearhead multi-stakeholder solutions that empower patients and disrupt systemic access barriers by 2025

Empowering Our Colleagues



38%

of employees at VP+ level are women (up from 24% in 2021)

20k+

volunteer hours logged by colleagues globally



Launched BeiGene Foundation



2024 GOALS

Reach global gender parity at the VP level and above by 2030

10k hours of global volunteerism (stretch goal of 15k hours)

Innovating Sustainably



Completed Scope 3 global footprint analyses for 2021 - 2023



Made progress towards developing a global product stewardship program through continued strategic work



2024 GOALS

Reduce scope 1 and 2 emissions by 25% per unit of internally manufactured commercial product by 2026 from a 2021 base year

Set a quantitative Scope 3 target by 2025

Operating Responsibly



Implemented third-party supplier risk management program



2024 GOALS

Develop a plan to better align key privacy performance metrics with sustainability best practices by 2025

Develop strategy to align with UNGC guidance on human rights by 2025